Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study

Therapy with low-dose amitriptyline is commonly used to treat painful diabetic peripheral neuropathy. There is a knowledge gap, however, regarding the role of variable CYP2D6-mediated drug metabolism and side effects (SEs). We aimed to generate pilot data to demonstrate that SEs are more frequent in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenomics 2017-04, Vol.18 (5), p.433-443
Hauptverfasser:	Chaudhry, Mamoonah, Alessandrini, Marco, Rademan, Jacobus, Dodgen, Tyren M, Steffens, Francois E, van Zyl, Danie G, Gaedigk, Andrea, Pepper, Michael S
Format:	Artikel
Sprache:	eng
Schlagworte:	Amitriptyline Amitriptyline - metabolism Amitriptyline - therapeutic use Analgesics, Non-Narcotic - metabolism Analgesics, Non-Narcotic - therapeutic use Antidepressants Consortia Constipation CYP2D6 protein Cytochrome Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - metabolism Cytochrome P450 Diabetes Diabetes mellitus Diabetic Neuropathies - diagnosis Diabetic Neuropathies - drug therapy Diabetic Neuropathies - genetics Diabetic neuropathy Drug dosages Drug metabolism Drug therapy Genetic diversity Genotype Genotype & phenotype Genotypes Humans Metabolism Metabolites Pain Patients Peripheral neuropathy Phenotypes Pilot Projects Public health Random Allocation Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!